We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ApoGraft

News List

Cellect Biotechnology Receives Approval for U.S. Clinical Trial americanpharmaceuticalreview
December 24, 2019
Cellect Biotechnology has received approval to initiate the trial in the U.S. to evaluate the safety and tolerability of the ApoGraft technology for haploidentical bone marrow transplantations.
FDA Grants Orphan Drug Status to ApoGraft for Acute and Chronic GvHD americanpharmaceuticacreview
September 06, 2017
Cellect Biotechnology announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cellect's ApoGraft for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.
FDA grants orphan drug status to Cellect’s ApoGraft europeanpharmaceuticalreview
September 06, 2017
The FDA has granted orphan drug designation for ApoGraft for the prevention of acute and chronic graft versus host disease…